查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1714723

再生医学市场按产品类型、来源、应用领域和最终用户划分－2025 年至 2030 年全球预测

Regenerative Medicine Market by Product Type, Source, Application Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计再生医学市场规模到 2024 年将达到 283.5 亿美元，到 2025 年将达到 349.9 亿美元，复合年增长率为 23.86%，到 ​​2030 年将达到 1,024 亿美元。

主要市场统计数据
基准年2024年 283.5亿美元
预计2025年 349.9亿美元
预测年份 2030 1024亿美元
复合年增长率（%） 23.86%

再生医学处于医疗保健模式转移的前沿，将生物技术的精确性与创新的治疗理念结合。该领域旨在恢復或建立受损组织和器官的正常功能，随着产业取得重大突破，该领域正在迅速发展。随着科学的进步和对人体的不断加深了解，再生医学有望治疗以前无法治癒的疾病，包括神经退化性疾病、心血管疾病和代谢紊乱。

透过利用细胞疗法、基因编辑和组织工程等尖端策略的潜力，研究人员正在更接近不仅可以治疗症状而且可以针对疾病根本原因的客製化解决方案。在新技术不断以前所未有的速度涌现的同时，研究界、临床医生和生物技术公司正在进行更广泛的合作，以弥合基础科学与临床应用之间的差距。目前的情况是由跨学科创新的复杂网络定义的，一个领域的突破推动着其他领域的进步。这种动态的相互作用使再生医学成为一个充满活力的探索领域，并为未来的个人化治疗性介入提供了重要基础。

该行业的持续发展受到支持性法规环境和投资涌入的推动。随着临床试验逐渐走出早期阶段，多种治疗方法逐渐接近实用化，综合涵盖新兴趋势和经过验证的科学见解的综合战略方针的重要性正变得越来越明显。进一步的变革正在酝酿中，这将重新定义现代医疗保健的界限。

改变再生医学市场

近年来，再生医学领域发生了巨大变化，重新定义了现代医疗保健的可能性。传统方法正在被新技术和新方法重新发明，挑战传统治疗方法的限制。基因编辑技术、先进的细胞治疗技术和创新的组织工程解决方案的快速发展不仅加快了发展步伐，而且极大地扩展了潜在的临床应用。

这种转变得益于对研发的大力投资，推动了曾经纯粹是科幻小说的治疗方法的商业化。前所未有的公私伙伴关係正在将实验室见解转化为现实世界的治疗方法。我们看到多学科专业知识的融合，工程师、生物学家和临床医生共同努力，确保治疗不仅有效，而且可扩展且经济可行。

这种转变的核心是数位健康解决方案和再生通讯协定的日益融合，它们共同促进了更个人化的治疗方法。利用人工智慧和资料分析的技术平台在简化临床试验、优化治疗製造和加强病患监测发挥关键作用。这种整体综合的方法将培育一个生态系统，以克服物流、监管和财务挑战，为创新、永续、以患者为中心的医疗保健新时代铺平道路。

再生医学关键环节分析

对再生医学的详细分析需要了解定义这个动态市场的广泛细分。从产品类型开始，该市场从多个维度进行考察，包括细胞疗法、细胞外疗法、细胞疗法、基因疗法和组织工程。细胞治疗本身复杂地分为非干细胞治疗和干细胞治疗，深入挖掘就会发现非干细胞治疗有复杂的子类别，例如免疫细胞和非免疫细胞。深入免疫细胞领域，细分变得更加细緻，包括树突状细胞、自然杀手细胞和 T 细胞。

基因疗法是这个多面向市场的另一个支柱，人们正在透过基因编辑技术、基因传递载体以及基于 RNA 和 DNA 的治疗方法进行密切研究。透过考虑非病毒和病毒载体之间的差异，将进一步完善基因转移载体的研究，强调区分这些方法的安全性和功效结果。组织工程同样细緻入微，因为它包括生物材料、生长因子和细胞激素以及支架等类别。生物材料领域本身很复杂，可分为天然生物材料和合成生物材料，它们在生物相容性和结构支持方面具有不同的优势。

市场区隔是根据供应来源和产品类型进行评估的。这考虑了来自同种异体、自体、合成和异种材料的治疗方法，每种治疗剂都存在监管和製造挑战。应用领域将进一步丰富分割矩阵，涵盖心血管、皮肤科、糖尿病、神经学、肿瘤学、眼科学、骨科和肌肉整形外科等临床频谱。在这些应用领域中，我们将在每个类别内进行进一步的研究。例如，心血管应用探索血管生成和血管重建、先天性心臟缺陷修復、心臟瓣膜置换和心肌梗塞治疗等方面，而皮肤病学则涉及美容手术、烧烫伤治疗和慢性创伤治疗。神经病学和其他学科保持着类似的细节水平，研究各种疾病的治疗方法，从阿兹海默症到脊髓损伤，再到肿瘤学中的肿瘤切除术。最后，按最终用户细分，市场主要分为学术和研究机构、受託研究机构、医院和诊所以及製药和生物技术公司，从而全面了解影响该行业的相关人员。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 慢性病的增加和创新治疗方法的需求
      • 个人化医疗意识和接受度的不断提高将推动再生医学的发展
      • 政府支持再生医学发展的措施和资金
    • 限制因素
      • 再生医学的开发成本高且製造复杂
    • 机会
      • 人工智慧主导的再生医学进步彻底改变了开发和个人化
      • 策略伙伴关係加速再生医学领域的创新和效率
    • 任务
      • 再生医学缺乏标准化和复杂的法规结构
  • 市场区隔分析
    • 产品类型：用于再生、替换和修復受损组织和器官的细胞疗法需求不断增长
    • 来源：自体再生医学对促进癒合和组织修復的重要性
    • 应用：整合肿瘤标靶化方法和肿瘤学中再生医学的组织修復
    • 最终用户：生物技术公司越来越多地采用再生医学，以利用尖端再生医学技术
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 再生医学市场（依产品类型）

  • 细胞疗法
    • 非干细胞疗法
      • 免疫细胞
      • 树突状细胞
      • 自然杀手（NK）细胞
      • T细胞
      • 非免疫细胞
    • 干细胞疗法
  • 细胞外和无细胞疗法
  • 基因治疗
    • 基因编辑技术
    • 基因转移载体
      • 非病毒载体
      • 病毒载体
    • 基于RNA和DNA的治疗方法
  • 组织工程
    • 生物材料
      • 天然生医材料
      • 合成生医材料
    • 生长因子和细胞激素
    • 鹰架

第七章 再生医学市场（依来源）

  • 同种异体
  • 自体移植
  • 合成
  • 异质

第八章 再生医学市场（依应用领域）

  • 心血管系统
    • 血管生成和血管重建
    • 先天性心臟疾病的修復
    • 心臟瓣膜置换术
    • 心肌梗塞的治疗
  • 皮肤科
    • 美容手术
    • 烧烫伤治疗
    • 慢性创伤治疗
  • 糖尿病
    • β细胞移植
    • 胰岛细胞再生
  • 神经病学
    • 阿兹海默症的治疗
    • 多发性硬化症的治疗
    • 帕金森氏症的治疗
    • 修復脊髓损伤
    • 中风復健
  • 肿瘤学
    • 癌症免疫治疗
    • 肿瘤消融
  • 眼科
    • 角膜修復
    • 视网膜再生
  • 整形外科和肌肉骨骼
    • 骨再生
    • 软骨修復
    • 肌腱修復

第九章 再生医学市场（依最终使用者）

  • 学术研究所
  • 合约研究组织
  • 医院和诊所
  • 製药和生物技术公司

第 10 章：美洲再生医学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第11章亚太再生医学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 12 章欧洲、中东和非洲的再生医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • 4D Molecular Therapeutics, Inc.
  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Astellas Pharma Inc.
  • Athersys, Inc.
  • Bayer AG
  • CMIC Co., Ltd.
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd.
  • Fate Therapeutics, Inc.
  • FUJIFILM Holdings Corporation
  • Gilead Sciences, Inc.
  • Integra LifeSciences Holdings Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson
  • Merck KGaA
  • Mesoblast Limited
  • Novartis AG
  • Orchard Therapeutics PLC
  • Organogenesis Holdings Inc.
  • Pluri Biotech Ltd.
  • Poseida Therapeutics, Inc.
  • REPROCELL Inc.
  • SanBio Company Limited
  • Stryker Corporation
  • Sumitomo Pharma Co., Ltd.
  • Sysmex Corporation
  • Takeda Pharmaceutical Company Limited
  • Tenaya Therapeutics, Inc.
  • Vericel Corporation
  • Voyager Therapeutics Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-430D42AA0F5B

The Regenerative Medicine Market was valued at USD 28.35 billion in 2024 and is projected to grow to USD 34.99 billion in 2025, with a CAGR of 23.86%, reaching USD 102.40 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 28.35 billion
Estimated Year [2025] USD 34.99 billion
Forecast Year [2030] USD 102.40 billion
CAGR (%) 23.86%

Regenerative medicine stands at the forefront of a paradigm shift in healthcare, melding the precision of biotechnology with innovative therapeutic concepts. This discipline, which strives to restore or establish normal function in damaged tissues and organs, is evolving rapidly as the industry makes significant breakthroughs. Driven by a convergence of scientific advancements and an ever-increasing understanding of the human body, regenerative medicine now holds promise for addressing previously incurable conditions such as neurodegenerative disorders, cardiovascular diseases, and metabolic dysfunctions.

Harnessing the potential of cutting-edge strategies like cell therapy, gene editing, and tissue engineering, researchers are moving closer to tailored solutions that not only treat symptoms but also target the root causes of disease. While new technologies continue to emerge at an unprecedented pace, the research community, clinicians, and biotech companies are collaborating more extensively to bridge fundamental science with clinical application. The current landscape is defined by an intricate network of interdisciplinary innovation, where breakthroughs in one area propel advances in another. This dynamic interplay ensures that regenerative medicine remains a vibrant arena of exploration and provides a vital foundation for the future of personalized therapeutic interventions.

The continuing evolution in this field is bolstered by supportive regulatory environments and an influx of investment. As clinical trials extend beyond early phases and some therapies edge closer to commercial viability, the importance of a comprehensive strategic approach that embraces both emerging trends and proven scientific insights becomes ever more apparent. The stage is set for further transformative changes that will redefine the boundaries of modern healthcare.

Transformative Shifts in the Regenerative Medicine Landscape

Recent years have witnessed dramatic transformative shifts within the regenerative medicine landscape that are redefining what is possible in modern healthcare. Legacy approaches are being reinvented, with new technologies and methodologies challenging the boundaries of traditional treatments. The rapid progression in gene editing technologies, advanced cell therapy techniques, and innovative tissue engineering solutions has not only accelerated the pace of development but has also dramatically expanded the potential applications in clinical practice.

These shifts are underpinned by robust investments in research and development, which have catalyzed the commercialization of therapies that once belonged purely to the realm of science fiction. Unprecedented partnerships across public and private sectors are enabling the translation of laboratory findings into real-world treatments. The landscape is witnessing a consolidation of interdisciplinary expertise where engineers, biologists, and clinicians collaborate to ensure therapies are not only effective but also scalable and economically viable.

At the core of this transformation is the increasing convergence of digital health solutions and regenerative protocols, which together contribute to more personalized treatment approaches. Technology platforms leveraging artificial intelligence and data analytics are playing a crucial role in streamlining clinical trials, optimizing therapy manufacturing, and enhancing patient monitoring. This holistic and integrated approach nurtures an ecosystem primed to overcome logistical, regulatory, and financial challenges, thus paving the way for a new era of innovative, sustainable, and patient-centered care.

Key Segmentation Insights in Regenerative Medicine

An in-depth analysis of regenerative medicine requires understanding the breadth of segmentation that defines this dynamic market. The market is studied across multiple dimensions beginning with product type, where it encompasses cell therapy, extracellular and acellular therapies, gene therapy, and tissue engineering. Within cell therapy itself lies a complex division into non-stem cell-based and stem cell-based therapies, and further exploration reveals the intricate sub-categories within non-stem cell-based therapy such as immune cells and non-immune cells. Delving deeper into the domain of immune cells, the segmentation becomes even more granular by distinguishing among dendritic cells, natural killer cells, and T cells, all of which are critical players in the emerging therapeutic landscape.

Gene therapy forms another pillar of this multi-faceted market and is carefully studied through the lens of gene editing technologies, gene transfer vectors, and RNA & DNA based therapies. The study of gene transfer vectors is further refined by considering the differences between non-viral and viral vectors, highlighting both the safety profiles and efficacy outcomes that differentiate these approaches. Tissue engineering is equally nuanced, as it involves categories such as biomaterials, growth factors & cytokines, and scaffolds. The area of biomaterials is complex in its own right, being segmented into natural and synthetic biomaterials that offer varying advantages in terms of biocompatibility and structural support.

Beyond product types, market segmentation is also evaluated based on source. This involves examining therapies derived from allogeneic, autologous, synthetic, and xenogeneic materials, each presenting unique regulatory and manufacturing challenges. Application areas further enrich the segmentation matrix, as they cover a spectrum of clinical fields including cardiovascular, dermatology, diabetes, neurology, oncology, ophthalmology, and orthopedic & musculoskeletal indications. Within such application areas, each category undergoes additional layers of study. For instance, cardiovascular applications explore dimensions such as angiogenesis and vascular regeneration, congenital heart defect repair, heart valve replacement, and myocardial infarction treatment, while dermatology addresses aesthetic procedures, burn treatment, and chronic wound healing. Neurology and other areas maintain a similar level of detail, scrutinizing therapies intended for conditions ranging from Alzheimer's disease to spinal cord injuries and tumor ablation in oncology. Finally, segmentation by end user dissects the market with a focus on academic and research institutes, contract research organizations, hospitals & clinics, and pharmaceutical and biotechnology companies, thereby offering a comprehensive view of the stakeholders influencing the field.

Based on Product Type, market is studied across Cell Therapy, Extracellular & Acellular Therapies, Gene Therapy, and Tissue Engineering. The Cell Therapy is further studied across Non-Stem Cell-Based Therapy and Stem Cell-Based Therapy. The Non-Stem Cell-Based Therapy is further studied across Immune Cells and Non-immune Cells. The Immune Cells is further studied across Dendritic Cells, Natural Killer (NK) Cells, and T Cells. The Gene Therapy is further studied across Gene Editing Technologies, Gene Transfer Vectors, and RNA & DNA-Based Therapies. The Gene Transfer Vectors is further studied across Non-Viral Vectors and Viral Vectors. The Tissue Engineering is further studied across Biomaterials, Growth Factors & Cytokines, and Scaffolds. The Biomaterials is further studied across Natural Biomaterials and Synthetic Biomaterials.

Based on Source, market is studied across Allogeneic, Autologous, Synthetic, and Xenogeneic.

Based on Application Areas, market is studied across Cardiovascular, Dermatology, Diabetes, Neurology, Oncology, Ophthalmology, and Orthopedic & Musculoskeletal. The Cardiovascular is further studied across Angiogenesis & Vascular Regeneration, Congenital Heart Defect Repair, Heart Valve Replacement, and Myocardial Infarction Treatment. The Dermatology is further studied across Aesthetic Procedures, Burn Treatment, and Chronic Wound Healing. The Diabetes is further studied across Beta Cell Transplantation and Islet Cell Regeneration. The Neurology is further studied across Alzheimer's Treatment, Multiple Sclerosis Therapy, Parkinson's Therapy, Spinal Cord Injury Repair, and Stroke Recovery. The Oncology is further studied across Cancer Immunotherapy and Tumor Ablation. The Ophthalmology is further studied across Corneal Repair and Retinal Regeneration. The Orthopedic & Musculoskeletal is further studied across Bone Regeneration, Cartilage Repair, and Tendon Repair.

Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies.

Regional Dynamics and Market Penetration Insights

Regenerative medicine has established a global footprint, with different regions showing distinctive trends in market penetration and growth. In the Americas, research initiatives and a robust funding environment have propelled advances in clinical application, making it one of the leading hubs for innovation in this field. The confluence of strong academic research, supportive healthcare policies, and venture capital investments underscores the region's prominent role in shaping global trends.

Across Europe, the Middle East, and Africa, the market is characterized by a blend of established innovation hubs and emerging research centers. Europe's regulatory frameworks and emphasis on clinical trials have fostered a cautious yet steady adoption of regenerative techniques. Meanwhile, the Middle East and Africa are gradually emerging as promising markets where investments in healthcare infrastructure and technology are beginning to bear fruit, thus contributing to a more balanced and diverse global landscape.

The Asia-Pacific region, driven by strategic government initiatives and expanding biotechnological expertise, is witnessing robust growth in regenerative medicine applications. Accelerated urbanization coupled with a rising middle class promotes demand for advanced therapies, while favorable government policies encourage research and collaborations, setting the stage for exponential market expansion. Across these regions, policy changes, technological advancements, and strategic funding initiatives continue to drive market penetration and provide valuable insights into the evolving dynamics of regenerative medicine on a global scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Major Companies Driving Innovation in Regenerative Medicine

The competitive landscape in regenerative medicine is marked by a diverse group of companies that are accelerating research and development while simultaneously pushing therapeutic boundaries. Key players such as 4D Molecular Therapeutics, Inc. and AbbVie Inc. bring extensive experience in biotherapeutics, while emerging innovators like Abeona Therapeutics Inc. and Adaptimmune Therapeutics PLC are at the forefront of pioneering novel approaches. Companies such as Adverum Biotechnologies, Inc. and AGC Biologics have established themselves by leveraging robust research platforms to address complex clinical challenges.

Other leaders, including Astellas Pharma Inc. and Athersys, Inc., combine clinical expertise with strategic investments to enhance their regenerative medicine portfolios. Recognized global entities such as Bayer AG contribute their longstanding pharmaceutical expertise, while CMIC Co., Ltd. and CRISPR Therapeutics AG integrate cutting-edge gene editing technologies into their development pipelines. Industry giants including F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., and FUJIFILM Holdings Corporation have also carved out significant roles in this domain.

Established players like Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., and Johnson & Johnson continue to push the envelope by investing in transformative medicine. Merging clinical insights with sustainable business strategies, companies such as Merck KGaA, Mesoblast Limited, and Novartis AG are leading the way in bringing innovative therapies to market. Meanwhile, fresh entrants such as Orchard Therapeutics PLC and Organogenesis Holdings Inc. work alongside companies like Pluri Biotech Ltd., Poseida Therapeutics, Inc., REPROCELL Inc., and SanBio Company Limited. This diverse ecosystem is complemented by contributions from Stryker Corporation, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Company Limited, Tenaya Therapeutics, Inc., Vericel Corporation, Voyager Therapeutics Inc., and Zimmer Biomet Holdings, Inc., each playing a pivotal role in propelling the future of regenerative medicine through continuous innovation and strategic market expansion.

The report delves into recent significant developments in the Regenerative Medicine Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., AbbVie Inc., Abeona Therapeutics Inc., Adaptimmune Therapeutics PLC, Adverum Biotechnologies, Inc., AGC Biologics, Astellas Pharma Inc., Athersys, Inc., Bayer AG, CMIC Co., Ltd., CRISPR Therapeutics AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, JCR Pharmaceuticals Co., Ltd., Johnson & Johnson, Merck KGaA, Mesoblast Limited, Novartis AG, Orchard Therapeutics PLC, Organogenesis Holdings Inc., Pluri Biotech Ltd., Poseida Therapeutics, Inc., REPROCELL Inc., SanBio Company Limited, Stryker Corporation, Sumitomo Pharma Co., Ltd., Sysmex Corporation, Takeda Pharmaceutical Company Limited, Tenaya Therapeutics, Inc., Vericel Corporation, Voyager Therapeutics Inc., and Zimmer Biomet Holdings, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders navigating the evolving landscape of regenerative medicine need to adopt a proactive strategy that encompasses investment in cutting-edge research, strategic partnerships, and the integration of advanced digital tools. To position themselves effectively, organizations should consider bolstering their research pipelines by investing in next-generation therapeutic platforms and ensuring robust portfolio diversification across various sub-segments. Firms are encouraged to actively pursue collaborations with academic institutions and contract research organizations to access novel technologies and emerging scientific insights, thereby accelerating the translational process from bench to bedside.

Furthermore, a systematic approach to digital transformation is paramount. Embracing data analytics, artificial intelligence, and advanced manufacturing techniques not only enhances operational efficiency but also fosters a more agile response to regulatory and market-driven changes. It is imperative to remain vigilant of evolving regulatory landscapes and to proactively engage with policymakers. Such engagement, coupled with comprehensive clinical data management and patient outcome monitoring, can optimize the pathway towards regulatory approvals and market access.

Lastly, tailoring strategies to address the unique regional and demographic drivers of demand will further solidify market position. For instance, customizing value propositions based on emerging market trends in regions such as the Americas, Europe, Middle East & Africa, and Asia-Pacific can offer significant competitive advantages. A detailed risk assessment, open innovation, and an adaptive business model will ensure long-term sustainable growth and secure a leadership position in the competitive realm of regenerative medicine.

Conclusion: Embracing the Future of Regenerative Medicine

The continuing evolution of regenerative medicine is not just a story of scientific brilliance, but a narrative of how collaborative innovation, strategic investments, and well-articulated market segmentation converge to create a transformative healthcare landscape. The current dynamic environment underlines the importance of integrating advanced therapeutic platforms with digital health solutions, thereby promising more personalized and effective treatment modalities.

Our analysis has systematically explored key facets of the market-from detailed segmentation based on product type, source, application areas, and end users, to the geographic nuances across the Americas, Europe, Middle East & Africa, and Asia-Pacific. It is clear that each segment provides unique insights into market trends and competitive dynamics, paving the way for novel therapeutic approaches and strategic partnerships. The contributions of major industry players accelerate these advancements, ensuring that breakthroughs in regenerative medicine will continue to shape a future characterized by improved patient outcomes and revolutionary treatment paradigms.

As the industry navigates through both transformative and sometimes turbulent shifts, embracing innovation and forming strategic alliances remain essential. The momentum gained not only reinforces current market trajectories but also sets the stage for further integration of interdisciplinary technologies, ultimately unlocking new possibilities in clinical practice and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases with the need for innovative treatments
      • 5.1.1.2. Growing awareness and acceptance of personalized medicine driving growth in regenerative therapies
      • 5.1.1.3. Government initiatives and funding to support the development of regenerative medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High development cost and manufacturing complexities associated with regenerative medicine
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements AI-driven regenerative medicine revolutionizing its development and personalization
      • 5.1.3.2. Strategic partnerships accelerating innovation and efficiency in regenerative medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of standardization and complex regulatory framework for regenerative medicine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Rising demand for cell therapy to regenerate, replace, and repair damaged tissues and organs
    • 5.2.2. Source: Significance of autologous regenerative medicine to promote healing and tissue repair
    • 5.2.3. Application Areas: Utilization of regenerative medicine in oncology to integrate tumor-targeting approaches with tissue restoration
    • 5.2.4. End User: Increased adoption of regenerative medicine across biotechnology companies to harness cutting-edge regenerative medicine technologies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Regenerative Medicine Market, by Product Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Non-Stem Cell-Based Therapy
      • 6.2.1.1. Immune Cells
      • 6.2.1.1.1. Dendritic Cells
      • 6.2.1.1.2. Natural Killer (NK) Cells
      • 6.2.1.1.3. T Cells
      • 6.2.1.2. Non-immune Cells
    • 6.2.2. Stem Cell-Based Therapy
  • 6.3. Extracellular & Acellular Therapies
  • 6.4. Gene Therapy
    • 6.4.1. Gene Editing Technologies
    • 6.4.2. Gene Transfer Vectors
      • 6.4.2.1. Non-Viral Vectors
      • 6.4.2.2. Viral Vectors
    • 6.4.3. RNA & DNA-Based Therapies
  • 6.5. Tissue Engineering
    • 6.5.1. Biomaterials
      • 6.5.1.1. Natural Biomaterials
      • 6.5.1.2. Synthetic Biomaterials
    • 6.5.2. Growth Factors & Cytokines
    • 6.5.3. Scaffolds

7. Regenerative Medicine Market, by Source

  • 7.1. Introduction
  • 7.2. Allogeneic
  • 7.3. Autologous
  • 7.4. Synthetic
  • 7.5. Xenogeneic

8. Regenerative Medicine Market, by Application Areas

  • 8.1. Introduction
  • 8.2. Cardiovascular
    • 8.2.1. Angiogenesis & Vascular Regeneration
    • 8.2.2. Congenital Heart Defect Repair
    • 8.2.3. Heart Valve Replacement
    • 8.2.4. Myocardial Infarction Treatment
  • 8.3. Dermatology
    • 8.3.1. Aesthetic Procedures
    • 8.3.2. Burn Treatment
    • 8.3.3. Chronic Wound Healing
  • 8.4. Diabetes
    • 8.4.1. Beta Cell Transplantation
    • 8.4.2. Islet Cell Regeneration
  • 8.5. Neurology
    • 8.5.1. Alzheimer's Treatment
    • 8.5.2. Multiple Sclerosis Therapy
    • 8.5.3. Parkinson's Therapy
    • 8.5.4. Spinal Cord Injury Repair
    • 8.5.5. Stroke Recovery
  • 8.6. Oncology
    • 8.6.1. Cancer Immunotherapy
    • 8.6.2. Tumor Ablation
  • 8.7. Ophthalmology
    • 8.7.1. Corneal Repair
    • 8.7.2. Retinal Regeneration
  • 8.8. Orthopedic & Musculoskeletal
    • 8.8.1. Bone Regeneration
    • 8.8.2. Cartilage Repair
    • 8.8.3. Tendon Repair

9. Regenerative Medicine Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Contract Research Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical & Biotechnology Companies

10. Americas Regenerative Medicine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Regenerative Medicine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Regenerative Medicine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. AskBio earns FDA advanced therapy designation for Parkinson's gene therapy to accelerate clinical trials and drive innovation in regenerative medicine
    • 13.3.2. Tenaya Therapeutics secures an USD 8 million grant from the California Institute for regenerative medicine
    • 13.3.3. UCLA researchers secure USD 21.8 million CIRM grant package to advance innovative stem cell and gene therapies
    • 13.3.4. Bio-Techne expands its R&D Systems portfolio with AI-engineered designer proteins to enhance regenerative medicine innovation
    • 13.3.5. Sysmex Corporation and J-TEC join forces to mechanize and automate regenerative medicine manufacturing processes
    • 13.3.6. Allogene Therapeutics receives FDA RMAT designation for ALLO-316
    • 13.3.7. Bioserve India leverages advanced stem cell tools and reprogramming kits to accelerate clinical trial outcomes and drive innovation in India's regenerative medicine market
    • 13.3.8. Sysmex launches innovative HISCL VEGF and PEDF assay kits to automate secreted protein measurement and reduce quality control costs for regenerative cellular medicine
    • 13.3.9. Cryoport and Minaris strategic partnership integrates advanced cold chain logistics with regenerative medicine
    • 13.3.10. STEMCELL Technologies expands its regenerative medicine platform by acquiring Maryland-based Propagenix
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Gilead Sciences, Inc.
    • 13.4.2. Novartis AG
    • 13.4.3. Bayer AG
    • 13.4.4. AbbVie Inc.

Companies Mentioned

  • 1. 4D Molecular Therapeutics, Inc.
  • 2. AbbVie Inc.
  • 3. Abeona Therapeutics Inc.
  • 4. Adaptimmune Therapeutics PLC
  • 5. Adverum Biotechnologies, Inc.
  • 6. AGC Biologics
  • 7. Astellas Pharma Inc.
  • 8. Athersys, Inc.
  • 9. Bayer AG
  • 10. CMIC Co., Ltd.
  • 11. CRISPR Therapeutics AG
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Fate Therapeutics, Inc.
  • 14. FUJIFILM Holdings Corporation
  • 15. Gilead Sciences, Inc.
  • 16. Integra LifeSciences Holdings Corporation
  • 17. JCR Pharmaceuticals Co., Ltd.
  • 18. Johnson & Johnson
  • 19. Merck KGaA
  • 20. Mesoblast Limited
  • 21. Novartis AG
  • 22. Orchard Therapeutics PLC
  • 23. Organogenesis Holdings Inc.
  • 24. Pluri Biotech Ltd.
  • 25. Poseida Therapeutics, Inc.
  • 26. REPROCELL Inc.
  • 27. SanBio Company Limited
  • 28. Stryker Corporation
  • 29. Sumitomo Pharma Co., Ltd.
  • 30. Sysmex Corporation
  • 31. Takeda Pharmaceutical Company Limited
  • 32. Tenaya Therapeutics, Inc.
  • 33. Vericel Corporation
  • 34. Voyager Therapeutics Inc.
  • 35. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. REGENERATIVE MEDICINE MARKET MULTI-CURRENCY
  • FIGURE 2. REGENERATIVE MEDICINE MARKET MULTI-LANGUAGE
  • FIGURE 3. REGENERATIVE MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 4. REGENERATIVE MEDICINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. REGENERATIVE MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. REGENERATIVE MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. REGENERATIVE MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. REGENERATIVE MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL KILLER (NK) CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY T CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-IMMUNE CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STEM CELL-BASED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY EXTRACELLULAR & ACELLULAR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE EDITING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RNA & DNA-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NATURAL BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC BIOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROWTH FACTORS & CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SCAFFOLDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY XENOGENEIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ANGIOGENESIS & VASCULAR REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONGENITAL HEART DEFECT REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MYOCARDIAL INFARCTION TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY AESTHETIC PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BURN TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CHRONIC WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BETA CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ISLET CELL REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ALZHEIMER'S TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY MULTIPLE SCLEROSIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PARKINSON'S THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY SPINAL CORD INJURY REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY STROKE RECOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TUMOR ABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CORNEAL REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY RETINAL REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY TENDON REPAIR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 118. ARGENTINA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 136. BRAZIL REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 141. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 150. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 154. CANADA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 159. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 161. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 162. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 163. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 166. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 168. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 172. MEXICO REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 177. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 179. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES REGENERATIVE MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 218. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 220. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 221. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 222. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 223. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 224. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 228. AUSTRALIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 232. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 233. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 235. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 236. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 237. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 238. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 239. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 240. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 242. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 244. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 246. CHINA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 249. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 251. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 252. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 253. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 254. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 255. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 256. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 257. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 258. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 260. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 264. INDIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 269. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 270. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 271. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 272. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 273. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 274. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 275. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 276. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 278. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 282. INDONESIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 285. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 287. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 289. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 290. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 291. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 292. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 293. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 294. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 296. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 299. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 300. JAPAN REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 301. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 303. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 305. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 307. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 308. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 309. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 311. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 312. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 313. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY DIABETES, 2018-2030 (USD MILLION)
  • TABLE 314. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY ORTHOPEDIC & MUSCULOSKELETAL, 2018-2030 (USD MILLION)
  • TABLE 318. MALAYSIA REGENERATIVE MEDICINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 321. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY NON-STEM CELL-BASED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 322. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY IMMUNE CELLS, 2018-2030 (USD MILLION)
  • TABLE 323. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 324. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY GENE TRANSFER VECTORS, 2018-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY TISSUE ENGINEERING, 2018-2030 (USD MILLION)
  • TABLE 326. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY BIOMATERIALS, 2018-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 328. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 329. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
  • TABLE 330. PHILIPPINES REGENERATIVE MEDICINE MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
  • TABLE 331. PHI